Arrowhead Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
Arrowhead Pharmaceuticals, Inc. (ARWR) filed this Current Report on Form 8-K on February 5, 2026. The filing announces the company's fiscal 2026 financial results for the period ended December 31, 2025. The company is incorporated in Delaware and trades on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. It serves as a notification that the fiscal 2026 results have been announced and commented upon by management.
Guidance, Outlook, and Risks
Management commentary regarding the fiscal 2026 results is referenced in the attached press release (Exhibit 99.1). The filing includes a standard disclaimer stating that the information in this report and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 5, 2026) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate based on the full fiscal 2026 results.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if there were any changes to the company's forward-looking guidance or strategic priorities.